Emerging role of innate immunity in organ transplantation part III: The quest for transplant tolerance via prevention of oxidative allograft injury and its consequences

Transplantation Reviews

Volumn 26, Issue 2, 2012, Pages 88-102

  Land, Walter G ^a  

^a German Academy for Transplantation Medicine   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ECULIZUMAB; ETANERCEPT; HEME OXYGENASE 1; IMISOPASEM MANGANESE; INFLAMMASOME; INFLIXIMAB; INTERLEUKIN 1BETA; M 40401; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; METHYLPREDNISOLONE; NORPHENAZONE; PATTERN RECOGNITION RECEPTOR; PEXELIZUMAB; ROTENONE; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; BRAIN ISCHEMIA; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; COMPLEX FORMATION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GRAFT DYSFUNCTION; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART GRAFT; HUMAN; IMMUNOREGULATION; IMMUNOSTIMULATION; INFLAMMATORY DISEASE; INNATE IMMUNITY; MOLECULARLY TARGETED THERAPY; NONHUMAN; ORGAN DONOR; ORGAN PERFUSION; ORGAN TRANSPLANTATION; REGULATORY T LYMPHOCYTE; REVIEW; SINGLE DRUG DOSE; TRANSPLANTATION TOLERANCE;

EID: 84859002866     PISSN: 0955470X     EISSN: 15579816     Source Type: Journal    
DOI: 10.1016/j.trre.2011.07.001     Document Type: Review

References (88)

1. Land W.G. Emerging role of innate immunity in organ transplantation. Part I: evolution of innate immunity and oxidative Allograft injury. Transplant Rev 2011, (in press).
2. Land W.G. Emerging role of innate immunity in organ transplantation. Part II: potential of DAMPs to generate immunostimulatory dendritic cells. Transplant Rev 2011, (in press).
3. Steinman R.M., Hawiger D., Nussenzweig M.C. Tolerogenic dendritic cells. Annu Rev Immunol 2003, 21:685-711.
4. + T cell tolerance. Immunity 2003, 18:713-720.
5. Morelli A.E., Thomson A.W. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol 2007, 7:610-621.
6. Bancherau J., Steinman R.M. Dendritic cell and the control of immunity. Nature 1998, 392:245-252.
7. Hawiger D., Inaba K., Dorsett Y., Guo M., Mahnke K., Rivera M., et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001, 194:769-779.
8. Mahnke K., Schmitt E., Bonifaz L., Enk A.H., Jonuleit H. Immature, but not inactive: the tolerogenic function of immature dendritic cells. Immunol Cell Biol 2002, 80:477-483.
9. Yamazaki S., Iyoda T., Tarbell K., Olson K., Velinzon K., Inaba K., Steinman R.M. Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J Exp Med 2003, 198:235-247.
10. Yamazaki S., Bonito A.J., Spisek R., Dhodapkar M., Inaba K., Steinman R.M. Dendritic cells are specialized accessory cells along with TGF-β for the differentiatiosn of Foxp3+CD4+ regulatory T cells from peripheral Foxp3 precursors. Blood 2007, 110:4293-4302.
11. Maldonado R.A., von Andrian U.H. How tolerogenic dendritic cells induce regulatory T cells. Adv Immunol 2010, 108:111-165.
12. Cobbold S.P., Castejon R., Adams E., Zelenika D., Graca L., Humm S., Waldmann H. Induction of foxP3 regulatory T cells in the periphery of T cell receptor transgenic mice tolerized to transplants. J Immunol 2004, 172:6003-6010.
13. Ochando J.C., Homma C., Yang Y., Hidalgo A., Garin A., Tacke F., et al. Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat Immunol 2006, 7:652-662.
14. Knechtle S.J. Immunoregulation and tolerance. Transplant Proc 2010, 42:S13-S15.
15. Issa F., Hester J., Goto R., Nadig S.N., Goodacre T.E., Wood K. Ex vivo-expanded human regulatory T cells prevent the rejection of skin allografts in a humanized Mouse model. Transplantation 2010, 90:1321-1327.
16. Nadig S.N., Wieckiewicz J., Wu D.C., Warnecke G., Zhang W., Luo S., et al. In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells. Nat Med 2010, 16:809-813.
17. Delamarre L., Mellman I. Harnessing dendritic cells for immunotherapy. Semin Immunol 2011, 23:2-11.
18. Land W.G. Innate alloimmunity. Part 2: innate immunity and allograft rejection 2011, Başkent University-Pabst Science Publishers, Ankara, Turkey.
19. Fu C., Jiang A. Generation of tolerogenic dendritic cells via the E-cadherin/β-catenin-signaling pathway. Immunol Res 2010, 46:72-78.
20. Manicassamy S., Reizis B., Ravindran R., Nakaya H., Salazar-Gonzalez R.M., Wang Y.C., et al. Activation of beta-catenin in dendritic cells regulates immunity versus tolerance in the intestine. Science 2010, 329:849-853.
21. Mellman I., Clausen B.E. Immunology. Beta-catenin balances immunity. Science 2010, 329:767-769.
22. Bar-On L., Birnberg T., Kim K.W., Jung S. Dendritic cell-restricted CD80/86 deficiency results in peripheral regulatory T-cell reduction but is not associated with lymphocyte hyperactivation. Eur J Immunol 2011, 41:291-298.
23. Bonifaz L., Bonnyay D., Mahnke K., Rivera M., Nussenzweig M.C., Steinman R.M. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 2002, 196:1627-1638.
24. Hawiger D., Masilamani R.F., Bettelli E., Kuchroo V.K., Nussenzweig M.C. Immunological unresponsiveness characterized by increased expression of CD5 on peripheral T cells induced by dendritic cells in vivo. Immunity 2004, 20:695-705.
25. Bluestone J., Abbas A. Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003, 3:253-257.
26. Wing K., Onishi Y., Prieto-Martin P., Yamaguchi T., Miyara M., Fehervari Z., et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008, 322:271-275.
27. Tang Q., Bluestone J.A. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol 2008, 9:239-244.
28. Vignali D., Collison L., Workman C. How regulatory T cells work. Nat Rev Immunol 2008, 8:523-532.
29. Daniel C., Nolting J., von Boehmer H. Mechanisms of self-nonself discrimination and possible clinical relevance. Immunotherapy 2009, 1:631-644.
30. Kendal A.R., Waldmann H. Infectious tolerance: therapeutic potential. Curr Opin Immunol 2010, 22:560-565.
31. Ostroukhova M., Seguin-Devaux C., Oriss T.B., Dixon-McCarthy B., Yang L., Ameredes B.T., et al. Tolerance induced by inhaled antigen involves CD4(+) T cells expressing membrane-bound TGF-beta and FOXP3. J Clin Invest 2004, 114:28-38.
32. Apostolou I., von Boehmer H. In vivo instruction of suppressor commitment in naive T cells. J Exp Med 2004, 199:1401-1408.
33. de Heer H.J., Hammad H., Soullie' T., Hijdra D., Vos N., Willart M.A.M., et al. Essential role of lung plasmacytoid dendritic cells in preventing asthmatic reactions to harmless inhaled antigen. J Exp Med 2004, 200:89-98.
34. Kretschmer K., Apostolou I., Hawiger D., Khazaie K., Nussenzweig M.C., von Boehmer H. Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol 2005, 6:1219-1227.
35. Tsuji N.M., Kosaka A. Oral tolerance: intestinal homeostasis and antigen-specific regulatory T cells. Trends Immunol 2008, 29:532-540.
36. Lambrecht B.N., Hammad H. Biology of lung dendritic cells at the origin of asthma. Immunity 2009, 31:412-424.
37. Stampfli M.R., Wiley R.E., Neigh G.S., Gajewska B.U., Lei X.F., Snider D.P., et al. GM-CSF transgene expression in the airway allows aerosolized ovalbumin to induce allergic sensitization in mice. J Clin Invest 1998, 102:1704-1714.
38. Eisenbarth S.C., Piggott D.A., Huleatt J.W., Visintin I., Herrick C.A., Bottomly K. Lipopolysaccharide-enhanced, toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen. J Exp Med 2002, 196:1645-1651.
39. Kretschmer K., Heng T.S., von Boehmer H. De novo production of antigen-specific suppressor cells in vivo. Nat Protoc 2006, 1:653-661.
40. Simpson E., Scott D., James E., Lombardi G., Cwynarski K., Dazzi F., et al. Minor H antigens: genes and peptides. Transpl Immunol 2002, 10:115-123.
41. Chai J.G., James E., Dewchand H., Simpson E., Scott D. Transplantation tolerance induced by intranasal administration of HY peptides. Blood 2004, 103:3951-3959.
42. Verginis P., McLaughlin K.A., Wucherpfennig K.W., von Boehmer H., Apostolou I. Induction of antigen-specific regulatory T cells in wild-type mice: visualization and targets of suppression. Proc Natl Acad Sci USA 2008, 105:3479-3484.
43. Daniel C., Ploegh H., von Boehmer H. Antigen-specific induction of regulatory T cells in vivo and in vitro. Methods Mol Biol 2011, 707:173-185.
44. Mitchison N.A. Induction of immunological paralysis in two zones of dosage. Proc Roy Soc 1964, 161:275-292.
45. Dresser D.W. Specific inhibition of antibody production. I. Protein-overloading paralysis. Immunology 1962, 5:161-168.
46. Dresser D.W. Specific inhibition of antibody production. II. Paralysis induced in mice by small quantities of protein antigen. Immunology 1962, 5:378-388.
47. Land W., Seifert J., Fateh-Moghadam A., Hopf U., Brendel W. Immunological tolerance induced in adult dogs by small amounts of horse IgG. Transplantation 1969, 8:748-750.
48. Brendel W., Land W., Hopf U., Seifert J. Induction of tolerance in man to horse-IgG. Lancet 1969, 2:1141-1142.
49. Land W.G. Immunosuppressive strategies in organ transplantation in the light of innate immunity. Exp Clin Transplant 2006, 4:406-415.
50. Land W.G. Innate immunity-mediated allograft rejection and strategies to prevent it. Transplant Proc 2007, 39:667-672.
51. Cypel M., Rubacha M., Yeung J., Hirayama S., Torbicki K., Madonik M., et al. Normothermic ex vivo perfusion prevents lung injury compared to extended cold preservation for transplantation. Am J Transplant 2009, 9:2262-2269.
52. Lambeth J.D., Krause K.H., Clark R.A. NOX enzymes as novel targets for drug development. Semin Immunopathol 2008, 30:339-363.
53. Jaquet V., Scapozza L., Clark R., Krause K.H., Lambeth J.D. Small molecule NOX inhibitors: ROS-generating NADPH oxidases as therapeutic targets. Antioxid Redox Signal 2009, 11:2535-2552.
54. Stefanska J., Sokolowska M., Sarniak A., Wlodarczyk A., Doniec Z., Nowak D., Pawliczak R. Apocynin decreases hydrogen peroxide and nitrate concentrations in exhaled breath in healthy subjects. Pulm Pharmacol Ther 2010, 23:48-54.
55. Southard J.H., Belzer F.O. Organ preservation. Annu Rev Med 1995, 46:235-247.
56. Chohan S., Becker M.A. Update on emerging urate-lowering therapies. Curr Opin Rheumatol 2009, 21:143-149.
57. Hu M., Tomlinson B. Febuxostat in the management of hyperuricemia and chronic gout: a review. Ther Clin Risk Manag 2008, 4:1209-1220.
58. Chen Q., Vazquez E.J., Moghaddas S., Hoppel C.L., Lesnefsky E.J. Production of reactive oxygen species by mitochondria: central role of complex III. J Biol Chem 2003, 278:36027-36031.
59. Kolamunne R.T., Clare M., Griffiths H.R. Mitochondrial superoxide anion radicals mediate induction of apoptosis in cardiac myoblasts exposed to chronic hypoxia. Arch Biochem Biophys 2011, 505:256-265.
60. Jung H.J., Shim J.S., Lee J., Song Y.M., Park K.C., Choi S.H., et al. Terpestacin inhibits tumor angiogenesis by targeting UQCRB of mitochondrial complex III and suppressing hypoxia-induced reactive oxygen species production and cellular oxygen sensing. J Biol Chem 2010, 285:11584-11595.
61. Masini E., Cuzzocrea S., Mazzon E., Marzocca C., Mannaioni P.F., Salvemini D. Protective effects of M40403, a selective superoxide dismutase mimetic, in myocardial ischaemia and reperfusion injury in vivo. Br J Pharmacol 2002, 136:905-917.
62. Watanabe T., Yuki S., Egawa M., Nishi H. Protective effects of MCI-186 on cerebral ischemia: possible involvement of free radical scavenging and antioxidant actions. J Pharmacol Exp Ther 1994, 268:1597-1604.
63. Watanabe T., Egawa M. Effects of an antistroke agent MCI-186 on cerebral arachidonate cascade. J Pharmacol Exp Ther 1994, 271:1624-1629.
64. Tahara M., Nakayama M., Jin M.B., Fujita M., Suzuki T., Taniguchi M., et al. A radical scavenger, edaravone, protects canine kidneys from ischemia-reperfusion injury after 72 hours of cold preservation and autotransplantation. Transplantation 2005, 80:213-221.
65. Tanaka K., Shirasugi N., Inoue F., et al. MCI-186 (free radical scavenger) induce prolonged survival of fully-allogeneic cardiac grafts. Am J Transplant 2004, 4:527.
66. Jurewicz M., Ueno T., Azzi J., Tanaka K., Murayama T., Yang S., et al. Donor antioxidant strategy prolongs cardiac allograft survival by attenuating tissue dendritic cell immunogenicity. Am J Transplant 2011, 11:348-355.
67. Tsuchihashi S., Fondevila C., Kupiec-Weglinski J.W. Hemeoxygenase system in ischemia and reperfusion injury. Ann Transplant 2004, 9:84-87.
68. Kotsch K., Francuski M., Pascher A., Klemz R., Seifert M., Mittler J., et al. Improved long-term graft survival after HO-1 induction in brain-dead donors. Am J Transplant 2006, 6:477-486.
69. Land W.G., Gutmann T., Daar A.S. Emerging science, emerging ethical issues: who should fund innate alloimmunity-suppressing drugs?. Acta Chir Belg 2008, 108:73-82.
70. Testa L., Van Gaal W.J., Bhindi R., Biondi-Zoccai G.G., Abbate A., Agostoni P., et al. Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients. J Thorac Cardiovasc Surg 2008, 136:884-893.
71. Wang H., Arp J., Liu W., Faas S.J., Jiang J., Gies D.R., et al. Inhibition of terminal complement components in presensitized transplant recipients prevents antibody-mediated rejection leading to long-term graft survival and accommodation. J Immunol 2007, 179:4451-4463.
72. Jordan S.C., Reinsmoen N., Peng A., Lai C.H., Cao K., Villicana R., et al. Advances in diagnosing and managing antibody-mediated rejection. Pediatr Nephrol 2010, 25:2035-2045.
73. Guttmann R.D., Beaudoin J.G., Morehouse D.D. Reduction of immunogenicity of human cadaver renal allografts by donor pretreatment. Transplant Proc 1973, 5:663-665.
74. Kauffman H.M., Sampson D., Fox P.S., Stawicki A.T. High dose (bolus) intravenous methylprednisolone at the time of kidney homotransplantation. Ann Surg 1977, 186:631-634.
75. Kotsch K., Ulrich F., Reutzel-Selke A., Pascher A., Faber W., Warnick P., et al. Methylprednisolone therapy in deceased donors reduces inflammation in the donor liver and improves outcome after liver transplantation: a prospective randomized controlled trial. Ann Surg 2008, 248:1042-1050.
76. Wanderer A.A. Ischemic-reperfusion syndromes: biochemical and immunologic rationale for IL-1 targeted therapy. Clin Immunol 2008, 128:127-132.
77. Rusai K., Huang H., Sayed N., Strobl M., Roos M., Schmaderer C., et al. Administration of interleukin-1 receptor antagonist ameliorates renal ischemia-reperfusion injury. Transpl Int 2008, 21:572-580.
78. Walker U.A., Hasler P. Safety and efficacy of biologics directed against TNF-alpha and CD20 in the therapy of vasculitis and systemic lupus erythematosus. Ther Umsch 2008, 65:303-310.
79. Pierer M., Baerwald C. Biological therapy for the treatment of rheumatic diseases. Internist (Berl) 2008, 49:938-946.
80. Zhang Z.X., Beduhn M.E., Zheng X., Min W.P., Jevnikar A.M. Preventing tissue injury using siRNA. Methods Mol Biol 2010, 623:341-355.
81. Li S., Tabar S.S., Malec V., Eul B.G., Klepetko W., Weissmann N., et al. NOX4 regulates ROS levels under normoxic and hypoxic conditions, triggers proliferation, and inhibits apoptosis in pulmonary artery adventitial fibroblasts. Antioxid Redox Signal 2008, 10:1687-1698.
82. Peshavariya H., Dusting G.J., Jiang F., Halmos L.R., Sobey C.G., Drummond G.R., Selemidis S. NADPH oxidase isoform selective regulation of endothelial cell proliferation and survival. Naunyn Schmiedebergs Arch Pharmacol 2009, 380:193-204.
83. Ben Mkaddem S., Pedruzzi E., Werts C., Coant N., Bens M., Cluzeaud F., et al. Heat shock protein gp96 and NAD(P)H oxidase 4 play key roles in Toll-like receptor 4-activated apoptosis during renal ischemia/reperfusion injury. Cell Death Differ 2010, 17:1474-1485.
84. Zhang X., Zheng X., Sun H., Feng B., Chen G., Vladau C., et al. Prevention of renal ischemic injury by silencing the expression of renal caspase 3 and caspase 8. Transplantation 2006, 82:1728-1732.
85. Zheng X., Feng B., Chen G., Zhang X., Li M., Sun H., et al. Preventing renal ischemia-reperfusion injury using small interfering RNA by targeting complement 3 gene. Am J Transplant 2006, 6:2099-2108.
86. Zheng X., Zhang X., Sun H., Feng B., Li M., Chen G., et al. Protection of renal ischemia injury using combination gene silencing of complement 3 and caspase 3 genes. Transplantation 2006, 82:1781-1786.
87. Sioud M. Promises and challenges in developing RNAi as a research tool and therapy. Methods Mol Biol 2011, 703:173-187.
88. Zhang X., Li M., Min W.P. Preventing immune rejection through gene silencing. Methods Mol Biol 2010, 623:357-371.